ProAssurance (PRA) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Net income for Q2 2024 was $15.5 million ($0.30 per diluted share), with operating earnings of $0.23 per share and a 16% increase in net investment income year-over-year, driven by higher interest rates and improved underwriting discipline.
Six-month net income rose to $20.1 million from $4.5 million year-over-year, and six-month operating earnings reached $0.31 per share.
Book value per share was $22.15, and non-GAAP adjusted book value per share was $26.18 at June 30, 2024.
Management remains focused on long-term balance sheet protection, disciplined capital management, and profitability over growth.
Specialty P&C segment saw 9% renewal pricing increases and 84% retention, with a focus on profitability.
Financial highlights
Net investment income for Q2 was $36.6 million, up 15.5% year-over-year, with new purchase yields at 6%.
Net premiums earned for Q2 were $239.9 million, down from $247.9 million; total revenues were $290.4 million, down 0.5% year-over-year.
Combined ratio for Q2 was 110.9%, up from 108.2% year-over-year.
Adjusted book value per share was just over $26, including $4 per share of unrealized holding losses.
Return on equity (annualized) was 5.5% for Q2.
Outlook and guidance
Management expects continued progress toward underwriting profitability in core business lines, despite market headwinds and loss environment.
Further rate increases are anticipated in response to rising loss severity trends.
CLARA Analytics platform expected to contribute to workers' comp processes in Q4 2024.
Cautious approach to growth will continue until market conditions improve.
Latest events from ProAssurance
- 2025 net income reached $50.9M, with improved ratios and a pending merger expected to close in 2026.PRA
Q4 202523 Feb 2026 - Q3 2024 net income rose to $16.4M as underwriting and investment results improved.PRA
Q3 202415 Jan 2026 - Operating and net income rose, with higher book value and strong investment returns.PRA
Q4 202423 Dec 2025 - Shareholders to vote on $25.00/share cash merger, board recommends approval, closing expected 2026.PRA
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay highlight a performance-driven, well-governed agenda.PRA
Proxy Filing1 Dec 2025 - Shareholders to vote on $25.00 per share cash merger; board unanimously recommends approval.PRA
Proxy Filing1 Dec 2025 - ProAssurance to be acquired by The Doctors Company in a $1.3B deal, closing first half 2026.PRA
Proxy Filing1 Dec 2025 - Acquisition will create the largest physician-owned medical malpractice insurer, pending approvals.PRA
Proxy Filing1 Dec 2025 - Acquisition by The Doctors Company advances, with key votes and regulatory steps outlined.PRA
Proxy Filing1 Dec 2025